PBMCs were isolated and stimulated ex vivo with PMA (50ng/ml) and ionomycin (750ng/ml) for three hours in the presence of GolgiStop. Cells were stained for CD3 and CD14 followed by fixation and intracellular staining for CD4, IL-17 and IL-10. The following gating strategy was employed: first, the live lymphocyte population was gated (a), then CD14-CD3+ cells (b), then CD3+CD4+ (c), and then doublets were excluded based on FSC-W vs. FSC-A (d). Total IL-17+ or IL-10+ cells were gated using the cell gates shown (e, f), which were based on negative control stains (FMO) (g, h).
. The increase in the percentage of IL-17+ CD4+ T cells in the blood of TNFi-treated patients is not due to differences in disease activity or patient characteristics.
Clinical parameters of disease and demographic data were collected from patients with RA receiving DMARD therapy (n=21) or TNFi therapy (n=11). Graphs show the median with interquartile range for disease activity score (DAS)28 (a); erythrocyte sedimentation rate (ESR, b); C-reactive protein (CRP, c); proportion of rheumatoid factor (RF) seropositive patients (d); age (e); disease duration (f) and gender distribution (g) of the patients in the two different treatment groups. The TNFi group was slightly enriched for males (18 vs. 36% male in DMARD vs. TNFi), however no significant differences were observed in the percentage Th17 cells between male and female patients (h). Data were normality tested followed by unpaired t-test or Mann-Whitney test. Patients receiving TNFi therapy had a slight increase in median disease duration relative to those on DMARD therapy (11 vs. 8 years, p<0.05), which probably reflects the fact that in the UK guidelines mandate that patients with RA must fail to respond to at least two different DMARDs before they qualify for TNFi therapy and are thus likely to have longer disease duration. CD4+ T cells and CD14+ monocytes were co-cultured with anti-CD3 mAb in the absence or presence of adalimumab. At day 3, cells were stimulated for 1.5 hours with PMA/ionomycin, followed by an IL-17 cytokine secretion assay and flow sorting. Representative example of IL-17+ cell purities before and after sorting using the IL-17 cytokine secretion assay. Lysates from IFN-γ-IL-17-CD4+ T cells (30 μl per lane) were run in parallel and blotted onto PVDF membrane. The blot was cut near the 50 kD marker to stain the >50 kD part with anti-IKZF3 and the <50 kD part with anti-beta-actin. The >50 kD blot was cut into two; one half was incubated with anti-IKZF3 (1:5,000) pre-incubated with IKZF3 peptide (40 μg/ml) and the other was incubated with anti-IKZF3 alone without pre-incubation with peptide (a). Equal loading was confirmed by beta-actin staining (b). CD4+ T cells and CD14+ monocytes were co-cultured with anti-CD3 mAb in the absence or presence of adalimumab. At day 3, cells were stimulated for 1.5 hours with PMA/ionomycin, followed by an IL-17 (Th17) or IFN- (Th1) cytokine secretion assay and flow sorting. Cells were washed with cold PBS followed by direct lysis in Laemmli buffer. Lysates were boiled for 5 min at 95°C and resolved by electrophoresis on a 4-12% Bis-Tris NuPAGE gel. Proteins were transferred onto a PVDF membrane which was cut horizontally near the 50 kD marker and probed with either anti-IKZF3 (a) or anti-betaactin (b), followed by horseradish peroxidase-conjugated polyclonal swine anti-rabbit immunoglobulins. The blot was developed with SuperSignal West Pico Substrate and signals were acquired with the ChemiDoc XRS+ System using Image Lab software.
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